% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Olubiyi:867774,
      author       = {Olubiyi, Olujide and Olagunju, Maryam O. and Strodel,
                      Birgit},
      title        = {{R}ational {D}rug {D}esign of {P}eptide-{B}ased {T}herapies
                      for {S}ickle {C}ell {D}isease},
      journal      = {Molecules},
      volume       = {24},
      number       = {24},
      issn         = {1420-3049},
      address      = {Basel},
      publisher    = {MDPI},
      reportid     = {FZJ-2019-06384},
      pages        = {4551 -},
      year         = {2019},
      abstract     = {Sickle cell disease (SCD) is a group of inherited disorders
                      affecting red blood cells, which is caused by a single
                      mutation that results in substitution of the amino acid
                      valine for glutamic acid in the sixth position of the
                      β-globin chain of hemoglobin. These mutant hemoglobin
                      molecules, called hemoglobin S, can polymerize upon
                      deoxygenation, causing erythrocytes to adopt a sickled form
                      and to suffer hemolysis and vaso-occlusion. Until recently,
                      only two drug therapies for SCD, which do not even fully
                      address the manifestations of SCD, were approved by the
                      United States (US) Food and Drug Administration. A third
                      treatment was newly approved, while a monoclonal antibody
                      preventing vaso-occlusive crises is also now available. The
                      complex nature of SCD manifestations provides multiple
                      critical points where drug discovery efforts can be and have
                      been directed. These notwithstanding, the need for new
                      therapeutic approaches remains high and one of the recent
                      efforts includes developments aimed at inhibiting the
                      polymerization of hemoglobin S. This review focuses on
                      anti-sickling approaches using peptide-based inhibitors,
                      ranging from individual amino acid dipeptides investigated
                      30–40 years ago up to more promising 12- and 15-mers under
                      consideration in recent years.},
      cin          = {ICS-6},
      ddc          = {540},
      cid          = {I:(DE-Juel1)ICS-6-20110106},
      pnm          = {553 - Physical Basis of Diseases (POF3-553)},
      pid          = {G:(DE-HGF)POF3-553},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:31842406},
      UT           = {WOS:000507299600129},
      doi          = {10.3390/molecules24244551},
      url          = {https://juser.fz-juelich.de/record/867774},
}